GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (STU:04X) » Definitions » Loans Receivable

Personalis (STU:04X) Loans Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Personalis Loans Receivable?

Personalis's Loans Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.


Personalis Loans Receivable Historical Data

The historical data trend for Personalis's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis Loans Receivable Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Personalis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Personalis Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Personalis Loans Receivable Related Terms

Thank you for viewing the detailed overview of Personalis's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (STU:04X) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.

Personalis (STU:04X) Headlines

No Headlines